52 Stocks Moving In Monday's Mid-Day Session

Gainers

  • Arvinas, Inc. ARVN shares jumped 103.4% to $60.87 after the company reported interim clinical data for its cancer treatment. The company said ARV-471 showed evidence of anti-tumor activity.
  • AnPac Bio-Medical Science Co., Ltd. ANPC gained 78.2% to $7.52 after the company said it made significant progress in detecting pre-cancer diseases.
  • Teligent, Inc. TLGT jumped 64.8% to $1.0389 after declining over 8% on Friday. A Special Meeting of Stockholders is scheduled to reconvene on Wednesday December 16.
  • Veru Inc. VERU shares climbed 60% to $10.17. Veru reported Phase 2 trial results for enobosarm for endocrine resistant metastatic breast cancer.
  • Rubius Therapeutics, Inc. RUBY gained 45.9% to $9.32 after declining around 17% on Friday.
  • Alexion Pharmaceuticals, Inc. ALXN shares jumped 30.4% to $157.71 after AstraZeneca plc AZN announced plans buy the company for $39 billion.
  • Recro Pharma, Inc. REPH gained 30.2% to $3.85 after climbing around 37% on Friday.
  • BioCardia, Inc. BCDA shares rose 30.1% to $3.70. BioCardia said it expects data safety monitoring board verbal feedback for interim data from Phase 3 CardiaAMP heart failure trial by the end of December 15, 2020.
  • Evelo Biosciences, Inc. EVLO surged 29.3% to $9.75 after jumping around 18% on Friday. Evelo Biosciences, last week, reported new clinical candidate in oncology.
  • Atomera Incorporated ATOM surged 21.4% to $13.14.
  • Marathon Patent Group, Inc. MARA shares gained 19.6% to $5.68 after declining 9% on Friday. HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $7.5 to $9. Marathon Patent Group last week purchased additional 10K S-19j Pro ASIC miners from Bitmain and announced plans to open a second data center.
  • DermTech, Inc. DMTK shares surged 19.4% to $13.72. DermTech, on Friday, announced Inclusion of its melanoma test in two continuing medical education sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium.
  • Alimera Sciences, Inc. ALIM gained 19% to $4.9747. Alimera Sciences, last week, reported the launch of ILUVIEN in The Netherlands.
  • 22nd Century Group, Inc. XXII surged 18.8% to $3.02 after climbing 18% on Friday.
  • Homology Medicines, Inc. FIXX rose 18.2% to $12.10.
  • Synlogic Inc SYBX shares gained 17.4% to $2.63 after the company announced plans to advance its cancer treatment into the combination therapy stage of its phase 1 trial.
  • Gatos Silver, Inc. GATO shares rose 16.6% to $8.77. Gatos Silver reported quarterly results last week.
  • Aligos Therapeutics, Inc. ALGS gained 16.5% to $25.76.
  • ReneSola Ltd SOL shares rose 16.4% to $6.45. HC Wainwright & Co. maintained ReneSola with a Buy and raised the price target from $4 to $12.
  • LogicBio Therapeutics, Inc. LOGC surged 15.8% to $8.88.
  • Syros Pharmaceuticals, Inc. SYRS shares rose 15.4% to $11.71.
  • Inseego Corp. INSG gained 15.4% to $15.87 after climbing 12% on Friday. The company on Thursday announced its 5G MiFi M2000 mobile hotspot is now available at T-Mobile and on Friday announced the availability of 5G MiFi M200 in Japan.
  • Chinook Therapeutics, Inc. KDNY surged 14.9% to $15.31. Chinook Therapeutics reported a license agreement with Morehouse School of Medicine for development of therapies in kidney diseases disproportionately affecting African Americans and underserved communities.
  • Apellis Pharmaceuticals, Inc. APLS rose 14.7% to $54.88. Apellis and Sobi last week reported top-lone results at 48 weeks from Phase 3 PEGASUS study of pegcetacoplan in PNH.
  • Prevail Therapeutics Inc. PRVL jumped 14.3% to $13.36. Prevail Therapeutics, last week, said first patient was dosed in Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations.
  • Nurix Therapeutics, Inc. NRIX shares surged 14% to $45.30.
  • C4 Therapeutics, Inc. CCCC gained 13.8% to $33.03.
  • Summit Wireless Technologies, Inc. WISA surged 13.7% to $2.97 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $3.5 price target.
  • Socket Mobile, Inc. SCKT climbed 13.6% to $3.0225 after the company announced it received a notice of forgiveness from Western Alliance Bank for the $1.06 million PPP loan.
  • GoHealth, Inc. GOCO surged 12% to $14.88.
  • Riot Blockchain, Inc. RIOT rose 10.6% to $9.58 after declining 7% on Friday.
  • Amarin Corporation plc AMRN rose 6.2% to $5.32 after the company said VACEPA Covid-19 Cardiolink-9 randomized trial suggests improvement in outpatient-reported Covid-19 symptoms.
  • Pluralsight, Inc. PS rose 6% to $20.10 after the company agreed to be acquired by private-equity firm Vista Equity Partners in an all-cash transaction for $20.26 per share..


Check out these big penny stock gainers and losers

Losers

  • Aerpio Pharmaceuticals, Inc. ARPO shares dipped 46.9% to $1.1950 after the company disclosed results from its phase 2 trial of Razuprotafib glaucoma. HC Wainwright & Co. maintained Aerpio Pharmaceuticals with a Neutral and lowered the price target from $2 to $1.5.
  • Greenwich LifeSciences, Inc. GLSI dropped 26.4% to $41.24 after declining over 22% on Friday. Greenwich LifeSciences last week shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.
  • SELLAS Life Sciences Group, Inc. SLS fell 24% to $6.36. SELLAS Life Sciences Group shares tumbled around 53% on Friday after the company reported follow-up data from a randomized Phase 2 VADIS trial of Nelipepimut-S in woman with ductal carcinoma in-situ of the breast.
  • Destination XL Group, Inc. DXLG fell 23.8% to $0.2397 after the company announced it would delist from the Nasdaq.
  • TechTarget, Inc. TTGT dropped 16.8% to $50.08 after the company reported a proposed offering of convertible senior notes.
  • Gamida Cell Ltd GMDA shares declined 15.8% to $8.36 after the company pushed back its timeline to submit a biologics license application from 2020 to 2H 2021 due to additional data requests from the Food and Drug Administration.
  • NextDecade Corporation NEXT dipped 15.7% to $2.91 after climbing 38% on Friday.
  • SolarWinds Corporation SWI fell 15% to $20.00 after the company said some of its products may have been affected by a highly sophisticated hack.
  • AMC Entertainment Holdings, Inc. AMC dropped 14.8% to $3.34.
  • Fusion Fuel Green PLC HTOO fell 14.6% to $16.82.
  • Vivos Therapeutics, Inc. VVOS shares fell 12.8% to $7.84. Vivos Therapeutics shares climbed around 50% on Friday after the company priced its IPO at $6 per share..
  • Immutep Limited IMMP fell 12.7% to $3.0450 after declining over 38% on Friday. Immutep last week reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer.
  • Xenetic Biosciences, Inc. XBIO fell 12.7% to $1.99. Xenetic Biosciences, last week, announced a roughly 2.45 million shares registered direct offering priced at $2.45 per share.
  • Fossil Group, Inc. FOSL dropped 12.1% to $11.68.
  • Team, Inc. TISI fell 11.6% to $9.82.
  • Virgin Galactic Holdings, Inc. SPCE shares fell 11.1% to $28.47. A test flight of the VSS Unity from Virgin Galactic returned home early after an ignition failure on Saturday.
  • NantHealth, Inc. NH dropped 10.5% to $3.08. NantHealth recently presented significant treatment insights at the 2020 San Antonio Breast Cancer Symposium in a time of need with the pandemic’s impact on cancer care.
  • Neos Therapeutics, Inc. NEOS fell 8.2% to $0.6350. Neos Therapeutics and Aytu Biosciences last week announced a merger agreement.
  • AstraZeneca PLC AZN fell 6.8% to $50.60 after the company announced it would acquire Alexion Pharmaceuticals for $39 billion in cash and stock.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasInformation TechnologyMid-Day MoversSemiconductorsTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!